Compare SIGIP & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Selective Insurance Group Inc. Depositary Shares each representing a 1/1000th interest in a share of 4.60% Non-Cumulative Preferred Stock Series B
| Metric | SIGIP | OSRHW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 2800 | 21 |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2023 |
| Metric | SIGIP | OSRHW |
|---|---|---|
| Price | $17.22 | $0.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | N/A |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | N/A |
| 52 Week High | N/A | N/A |
| Indicator | SIGIP | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 56.77 | 58.72 |
| Support Level | $16.68 | $0.06 |
| Resistance Level | $17.23 | $0.07 |
| Average True Range (ATR) | 0.13 | 0.01 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 82.61 | 91.12 |
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, Investments. Majority of revenue is gained from Standard Personal Lines. Currently company has it's revenues from States of USA and Columbia.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.